🟢 positive (FOLLOW) · 🟡 wait (WAIT) · 🔴 bad/avoid (FADE/AVOID) · 🚨 major news

The market is in a broad panic-selling state (S&P 500 -3.7%, Nasdaq -5.3%), with the VIX surging to 35.89, reflecting extreme fear despite cooling 10-year yields. There are signs of heavy outflows from traditional safe-haven assets like gold into speculative channels such as Bitcoin, putting traders on strict defensive footing with a two-sided hedging strategy for every position.

Hot spots

🚨 🟢 REGN: FDA officially approves Livsayis for gMG, creating a direct catalyst for long-term revenue.

🚨 🟢 AZN: FDA approves Imfinzi for bladder cancer, strengthening its specialty pharmaceutical portfolio.

🟢 MRK: Efinopegdutide meets MASH trial endpoint and wins Keytruda case in Germany, removing significant legal pressure.

🟢 PFE: Blackstone invests in obesity drugs, alongside promising results from a pediatric pneumococcal vaccine, supporting core cash flow.

🟢 LLY: Joins an $87 million funding round for a Lyme disease vaccine project, expanding its portfolio and diversifying risk.

Use caution

🔴 MRNA: Facing a wave of fierce criticism over vaccine safety, with legal and regulatory risks rising sharply.

🚨 🟡 MDT: Hugo system receives FDA approval (old news from 17/11); the market has already priced it in, so don't FOMO into this news.

Recommended

The market is oversold; prioritize healthcare stocks with specific catalysts, such as REGN and AZN, rather than trying to catch falling stocks with no momentum. Maintain a tight hedge while VIX is at 35.89; only add to positions once there is confirmation of a reversal in money flows at firm technical support levels.

🚨 BIG NEWS — REGN: FDA APPROVES LIVSAYIS FOR gMG

🟢 REGN — HEALTHCARE-FDA — FOLLOW

Top news: FDA officially approves Livsayis, a siRNA drug for gMG with dosing every 3 months.

Significance: The new approval directly expands the specialty pharmaceutical portfolio, creates a new revenue stream, and strengthens Regeneron's position in the rare disease segment, which faces relatively little competition.

Action (1D): confirm on close above 1019.0 (upper BB) · invalidated on close below 912.9 (middle BB) · price 920.7 · RSI14/50/99 57/59/58

Sources: Quantisnow 19/11, ad-hoc-news.de 21/11

🚨 BIG NEWS — MDT: OLD NEWS (17/11): HUGO SYSTEM RECEIVES FDA APPROVAL

🟡 MDT — HEALTHCARE-FDA — WAIT

Top news: FDA approves the Hugo surgical system. (Original event on 17/11, already reflected in the price).

Significance: Old news; the market has already priced it in. There are no new developments to further affect the current growth trajectory.

Action (1D): bullish on close above 100.2 (middle BB) · bearish on close below 94.63 (MA50) · price 99.94 · RSI14/50/99 54/57/60

Sources: ad-hoc-news.de 21/11, Investing.com 17/11

🚨 BIG NEWS — AZN: IMFINZI APPROVED BY FDA FOR BLADDER CANCER

🟢 AZN — REGULATORY-APPROVAL — FOLLOW

Top news: Imfinzi receives U.S. approval for bladder cancer treatment.

Significance: This positive regulatory development expands the indication for a flagship drug, strengthening oncology revenue—a key growth pillar for the company.

Action (1D): confirm on close above 180.0 (MA200) · invalidated on close below 170.7 (MA50) · price 174.4 · RSI14/50/99 44/51/51

Source: ad-hoc-news.de 21/11

🟢 MRK — HEALTHCARE-FDA — FOLLOW

Headline: Efinopegdutide posts trial results; Keytruda wins case in Germany

Top news: Efinopegdutide meets MASH trial endpoint; German court overturns Keytruda SC ban.

Significance: The combination of an IP lawsuit victory and successful clinical trial results reduces legal risk and strengthens the future product pipeline.

Action (1D): confirm on close above 134.6 (lower BB) · invalidated on close below 129.2 (MA200) · price 133.7 · RSI14/50/99 34/48/56

Sources: ad-hoc-news.de 21/11, StreetInsider 19/11, Yahoo Finance 21/11, CASRAI 20/11, Endpoints News 19/11

🔴 MRNA — HEALTHCARE-FDA — AVOID

Headline: Facing a wave of fierce criticism over flu-COVID vaccines

Top news: Experts call for suspension of flu-COVID mRNA vaccines over safety concerns.

Significance: Public pressure and medical safety concerns create legal risks, directly threatening the rollout of key vaccine lines.

Action (1D): confirm on close below 182.0 (lower BB) · invalidated on close above 207.9 (MA50) · price 195.0 · RSI14/50/99 41/54/56

Sources: Yahoo Finance 21/11, Rebel News 21/11, Science, Public Health Policy and the Law 21/11, Simply Wall St 21/11

🟢 PFE — PARTNERSHIP-CUSTOMERS — FOLLOW

Headline: Blackstone funds obesity drug program; pediatric vaccine shows promise

Top news: Blackstone invests in obesity drugs; pediatric pneumococcal vaccine delivers strong immune response.

Significance: Blackstone's funding significantly eases R&D cost pressures (burn rate) in the obesity segment, while the new vaccine strengthens the outlook for sustainable revenue.

Action (1D): confirm on close above 27.48 (lower BB) · invalidated on close below 27.03 (MA200) · price 27.40 · RSI14/50/99 32/48/53

Sources: ad-hoc-news.de 21/11, Infectious Disease Special Edition 21/11, Quiver Quantitative 21/11, RegMedNet 20/11

🟢 LLY — HEALTHCARE-FDA — FOLLOW

Headline: Eli Lilly invests $87 million in Lyme disease vaccine development

Top news: LLY joins an $87 million funding round for a Lyme disease vaccine project.

Significance: The investment reflects a strategy to expand the R&D portfolio, diversifying revenue beyond current flagship drugs by securing a position in new vaccine technology. This move strengthens its position in the immunology segment. Technically, the price is consolidating positively above the MA50 (+6.3%), reflecting steady demand despite broader market correction pressure.

Action (1D): confirm on close above 1383.9 (middle BB) · invalidated on close below 1281.3 (lower BB) · price 1347.1 · RSI14/50/99 49/56/58

Sources: Simply Wall St 21/11, Simply Wall St 20/11

🟢 MCK — STRATEGY — FOLLOW

Headline: McKesson expands its oncology and multispecialty care operations

Top news: MCK is implementing a strategy to expand its capabilities in oncology and multispecialty care.

Significance: Deeper penetration into specialty segments helps optimize margins, as these areas have high technical barriers and sustained demand. Strengthening specialized healthcare supply chains generates stable revenue that is less sensitive to economic cycles than broad-based retail. Technically, the stock is in a strong uptrend (+9.8% versus MA50), and an RSI of 60 indicates momentum remains solid.

Action (1D): confirm on close above 1139.1 (upper BB) · invalidated on close below 1045.5 (middle BB) · price 1069.4 · RSI14/50/99 60/61/59

Source: Simply Wall St 21/11

⚠️ Based only on NEWS HEADLINES (Yahoo/Google News RSS). Insider stock sales are often made according to predetermined plans. Not investment advice.

⚠️ Not investment advice.📊🪙Finance Trader🪙📊“Do less, make more. It’s all about efficiency”🗽💰TraderKA_M8Capital

#GlobalStocksFaceLongestLosingStreakSince2023